News | October 08, 2012

Cook Medical Launches Zilver Vena Venous Self-Expanding Stent in Canada

Zilver Vena is Canada’s only venous stent indicated for use in the iliofemoral veins

Cook Medical Zilver Vena Venous Self-Expanding Stent

October 8, 2012 — Following Health Canada approval, Cook Medical made the Zilver Vena Venous Self-Expanding Stent available to physicians across Canada at the 2012 Annual Meeting of the Canadian Society for Vascular Surgery. Designed to restore blood flow in obstructed iliofemoral veins, Zilver Vena provides physicians with a tool designed specifically for stenting obstructed iliofemoral veins. This condition can arise for various reasons, including post-thrombotic syndrome in deep vein thrombosis (DVT) patients.

According to a study by Dr. A. Rosales of the department of vascular surgery at Oslo University Hospital in Norway, post-thrombotic syndrome (PTS) characterized by reflux and/or obstruction can be expected to develop in up to 40 percent of DVT patients.[1]

Built on Cook’s established line of Zilver stents, the Zilver Vena stent is a flexible, self-expanding stent made with “shape memory” nitinol. Zilver Vena was developed to address a challenging clinical issue, the need to establish and maintain blood flow in obstructed iliofemoral veins.

The stent provides flexibility, consistent radial force and continuous stent-to-vein wall apposition from end to end. Zilver Vena is currently available in 14 and 16 mm diameters and 60, 100 and 140 mm lengths to enable precise placement, and is compatible with 7 French sheaths and 9 French guiding catheters.

“As the only device of its kind available in Canada, Zilver Vena gives physicians a new treatment option for stenting diseased veins,” said Rob Lyles, vice president and global leader of Cook Medical’s Peripheral Intervention clinical division.

The Zilver Vena stent is currently under regulatory review by the U.S. Food and Drug Administration (FDA) and is not approved for sale in the United States.

For more information: www.cookmedical.com

Reference:

1. Rosales A. Sandbaek G, Jørgensen JJ. "Stenting for chronic post-thrombotic vena cava and iliofemoral venous occlusions: mid-term patency and clinical outcome." Eur J Vasc Endovasc Surg. 2010;40(2):234-240.

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
Overlay Init